RLAY Stock Forecast & Price Target

Relay Therapeutics is supported by a promising clinical pipeline, especially zovegalisib, whose vascular anomalies data showed 60% of response-evaluable patients achieving a volumetric response at 12 weeks and only 15% experiencing grade 3+ treatment-related adverse events, suggesting differentiated efficacy and tolerability versus alpelisib. The company also has meaningful near-term catalysts in breast cancer and vascular anomalies, including a planned regulatory/data update by end-2026, an expected Phase 3 enrollment update by YE26, and a next data cut in 1H27, while the 109-patient pooled efficacy/safety dataset in 2L breast cancer strengthens confidence in the program. Financially, Relay reported a 2Q26 net loss of $0.41 per share, spent $76.5M on R&D and $14.7M on SG&A, and ended 2Q26 with $910.9M in cash, which should fund operations into 2029 and support multiple value-driving milestones.

Relay Therapeutics is exposed to substantial clinical risk because drug development is inherently uncertain, and its assets may fail to demonstrate sufficient efficacy or safety in current or future trials. It also faces material regulatory and commercial risk, since approval from the FDA and foreign regulators is required before any meaningful market opportunity can be realized, and delays or denials would impair shareholder value. In addition, the company operates in a fiercely competitive oncology landscape against better-resourced biotechnology and pharmaceutical peers, while likely needing additional equity financing to fund development, which raises dilution risk for existing shareholders.